SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free OnlineFirst PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wenzel, U. O.
Right arrow Articles by Benndorf, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wenzel, U. O.
Right arrow Articles by Benndorf, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

The angiotensin II type 2 receptor in renal disease

Ulrich Otto Wenzel1*, Christian Krebs1, and Ralf Benndorf2

1 Department of Medicine, Division of Nephrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
2 Department of Medicine, Division of Pharmacology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

* To whom correspondence should be addressed. E-mail: wenzel{at}uke.uni-hamburg.de.


   Abstract

Suppression of angiotensin II formation by angiotensin-converting enzyme inhibitors or blockade of the angiotensin II receptor by angiotensin receptor blockers is a powerful therapeutic strategy to slow the progression of renal disease. However, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers provide only imperfect protection against the progression of chronic kidney disease to end-stage renal failure. Hence, innovative approaches are needed to keep patients with chronic kidney disease off dialysis. Angiotensin II activates at least two receptors, namely the angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2) receptors. The majority of the effects of angiotensin II, such as vasoconstriction, inflammation, and matrix deposition, are mediated via the AT1 receptor. It is thought that the AT2 receptor counteracts these effects and plays a role in nephroprotection. However, recent data support the notion that the AT2 receptor transduces pro-inflammatory effects and promotes fibrosis and hypertrophy. Therefore, the question of whether stimulation of the AT2 receptor could represent a silver bullet for the treatment of chronic kidney disease or may, on the contrary, exert detrimental effects on renal physiology remains unresolved. Recent data from AT2 receptor-knockout mice demonstrate that the loss of AT2 receptor signalling is associated with increased renal injury and mortality in chronic kidney disease. This raises the expectation that pharmacological stimulation of the AT2 receptor may positively influence renal pathologies. However, further research is needed to explore the question whether AT2 receptor stimulation may represent a new therapeutic strategy for the treatment of chronic kidney disease.

First published on October 27, 2009
Journal of Renin-Angiotensin-Aldosterone System 2009, doi:10.1177/1470320309347787


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement